Last reviewed · How we verify
ASC41
ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism.
ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism. Used for Non-alcoholic steatohepatitis (NASH), Hypercholesterolemia.
At a glance
| Generic name | ASC41 |
|---|---|
| Sponsor | Ascletis Pharmaceuticals Co., Ltd. |
| Drug class | Thyroid hormone receptor beta agonist |
| Target | THRβ |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 1 |
Mechanism of action
By activating the thyroid hormone receptor beta, ASC41 enhances the expression of genes involved in lipid metabolism, potentially reducing levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides.
Approved indications
- Non-alcoholic steatohepatitis (NASH)
- Hypercholesterolemia
Common side effects
- Headache
- Nausea
Key clinical trials
- Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects (PHASE1)
- Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH (PHASE2)
- Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects (PHASE1)
- DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD. (PHASE1)
- Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers (PHASE1)
- A Study of the Relative Bioavailability of ASC41 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |